Janux Therapeutics, Inc.’s JANX share price has dipped by 5.83%, which has investors questioning if this is right time to buy.

Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71. The firm’s fifty day moving average is $30.08 and its 200 day moving average is $43.13.

Janux Therapeutics' lead program, JANX007, shows promising early results in prostate cancer, with significant PSA declines and no serious side effects reported. The company's strong financial ...

JANX has generated some compelling early data in prostate cancer on a novel immunotherapy platform. Unfortunately, early results do not guarantee success, which is what the market is pricing in ...

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology.

Janux Therapeutics has a 1-year low of $26.03 and a 1-year high of $71.71. Janux Therapeutics ( NASDAQ:JANX – Get Free Report ) last issued its earnings results on Thursday, February 27th.

SAN DIEGO, February 27, 2025--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Janux Therapeutics Inc (Symbol: JANX) entered into oversold territory, hitting an RSI ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Monday, H.C. Wainwright adjusted its price target for Janux Therapeutics (NASDAQ:JANX) shares, increasing it to $63.00 from the ...

On Tuesday, Stifel reiterated its Buy rating on Janux Therapeutics (NASDAQ: JANX) with a steady price target of $70.00, ...